IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v14y2023i1d10.1038_s41467-023-39874-8.html
   My bibliography  Save this article

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

Author

Listed:
  • Joao V. Alessi

    (Dana-Farber Cancer Institute)

  • Biagio Ricciuti

    (Dana-Farber Cancer Institute)

  • Xinan Wang

    (Harvard University)

  • Federica Pecci

    (Dana-Farber Cancer Institute)

  • Alessandro Di Federico

    (Dana-Farber Cancer Institute)

  • Giuseppe Lamberti

    (Dana-Farber Cancer Institute)

  • Arielle Elkrief

    (Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center)

  • Scott J. Rodig

    (Brigham and Women’s Hospital
    Brigham and Women’s Hospital)

  • Emily S. Lebow

    (Memorial Sloan Kettering Cancer Center)

  • Jordan E. Eicholz

    (Memorial Sloan Kettering Cancer Center)

  • Maria Thor

    (Memorial Sloan Kettering Cancer Center)

  • Andreas Rimner

    (Memorial Sloan Kettering Cancer Center)

  • Adam J. Schoenfeld

    (Memorial Sloan Kettering Cancer Center)

  • Jamie E. Chaft

    (Memorial Sloan Kettering Cancer Center)

  • Bruce E. Johnson

    (Dana-Farber Cancer Institute)

  • Daniel R. Gomez

    (Memorial Sloan Kettering Cancer Center)

  • Mark M. Awad

    (Dana-Farber Cancer Institute)

  • Narek Shaverdian

    (Memorial Sloan Kettering Cancer Center)

Abstract

Although concurrent chemoradiation (CRT) and durvalumab consolidation has become a standard treatment for stage III non-small cell lung cancer (NSCLC), clinicopathologic and genomic factors associated with its efficacy remain poorly characterized. Here, in a multi-institutional retrospective cohort study of 328 patients treated with CRT and durvalumab, we identify that very high PD-L1 tumor proportion score (TPS) expression ( ≥ 90%) and increased tumor mutational burden (TMB) are independently associated with prolonged disease control. Additionally, we identify the impact of pneumonitis and its timing on disease outcomes among patients who discontinue durvalumab: compared to patients who experienced early-onset pneumonitis (

Suggested Citation

  • Joao V. Alessi & Biagio Ricciuti & Xinan Wang & Federica Pecci & Alessandro Di Federico & Giuseppe Lamberti & Arielle Elkrief & Scott J. Rodig & Emily S. Lebow & Jordan E. Eicholz & Maria Thor & Andre, 2023. "Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    • Handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-39874-8
    DOI: 10.1038/s41467-023-39874-8
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-39874-8
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-023-39874-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Su, Pei-Fang & Chi, Yunchan & Li, Chung-I & Shyr, Yu & Liao, Yi-De, 2011. "Analyzing survival curves at a fixed point in time for paired and clustered right-censored data," Computational Statistics & Data Analysis, Elsevier, vol. 55(4), pages 1617-1628, April.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Su, Pei-Fang & Li, Chung-I & Shyr, Yu, 2014. "Sample size determination for paired right-censored data based on the difference of Kaplan–Meier estimates," Computational Statistics & Data Analysis, Elsevier, vol. 74(C), pages 39-51.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-39874-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.